The U.S. Food and Drug Administration approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. Breast cancer is the second leading cause of cancer related death among women, according to the National Cancer Institute...
More...
Linear Mode
